Satellos Bioscience Inc. (MSCL.V)
| Previous Close | 0.4500 |
| Open | 0.4500 |
| Bid | 0.4000 x N/A |
| Ask | 0.4200 x N/A |
| Day's Range | 0.4200 - 0.4500 |
| 52 Week Range | 0.2200 - 0.8500 |
| Volume | |
| Avg. Volume | 42,889 |
| Market Cap | 47.373M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights
TORONTO, November 22, 2023--Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the three months ending September 30, 2023. All references to currency in this press release are in Canadian dollars unless otherwise noted.
- Business Wire
Satellos to Present at the Piper Sandler 35th Annual Healthcare Conference
TORONTO, November 20, 2023--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present and participate in the Piper Sandler 35th Annual Healthcare Conference taking place November 28-30 in New York City.
- Business Wire
Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program
TORONTO, November 14, 2023--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSXV: MSCL) (OTCQB: MSCLF), a publicly traded biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the following updates: AAK1 is the drug target of the Company’s lead drug program in Duchenne muscular dystrophy ("Duchenne" or "DMD"); IND-enabling studies and GMP manufacturing are ongoing; SAT-3247 has been nominated as its
